Results 11 to 20 of about 13,550 (188)

Structural insights into the molecular mechanism of high-level ceftazidime–avibactam resistance conferred by CMY-185 [PDF]

mBio
β-Lactamases can accumulate stepwise mutations that increase their resistance profiles to the latest β-lactam agents. CMY-185 is a CMY-2-like β-lactamase and was identified in an Escherichia coli clinical strain isolated from a patient who underwent ...
Akito Kawai, William C. Shropshire, Masahiro Suzuki, Jovan Borjan, Samuel L. Aitken, William C. Bachman, Christi L. McElheny, Micah M. Bhatti, Ryan K. Shields, Samuel A. Shelburne, Yohei Doi   +10 more
doaj   +4 more sources

Increased zinc levels facilitate phenotypic detection of ceftazidime-avibactam resistance in metallo-β-lactamase-producing Gram-negative bacteria [PDF]

Frontiers in Microbiology, 2022
Ceftazidime-avibactam is one of the last resort antimicrobial agents for the treatment of carbapenem-resistant, Gram-negative bacteria. Metallo-β-lactamase-producing bacteria are considered to be ceftazidime-avibactam resistant. Here, we evaluated a semi-
Michaela Simon, Michaela Simon, Roman G. Gerlach, Yvonne Pfeifer, Niels Pfennigwerth, Sören G. Gatermann, Agnes Schröder, Agnes Schröder, Andreas Hiergeist, Axel Hamprecht, Axel Hamprecht, Axel Hamprecht, Axel Hamprecht, Tamara Rügamer, André Gessner, Jonathan Jantsch, Jonathan Jantsch   +16 more
doaj   +4 more sources

Colistin Does Not Potentiate Ceftazidime-Avibactam Killing of Carbapenem-Resistant Enterobacteriaceae In Vitro or Suppress Emergence of Ceftazidime-Avibactam Resistance [PDF]

Antimicrobial Agents and Chemotherapy, 2018
We tested ceftazidime-avibactam and colistin against 24 carbapenem-resistant Enterobacteriaceae (CRE) isolates by time-kill studies. Ceftazidime-avibactam at 0.25×, 1×, and 4× the MIC was bactericidal against 8%, 21%, and 88% of the isolates, respectively.
Ryan K, Shields, M Hong, Nguyen, Binghua, Hao, Ellen G, Kline, Cornelius J, Clancy   +4 more
openaire   +3 more sources

A Selective Medium for Screening Ceftazidime/Avibactam Resistance in Carbapenem-Resistant Enterobacterales [PDF]

Frontiers in Microbiology, 2022
Ceftazidime/avibactam (CZA) is an alternative antibiotic used for the treatment of infections caused by carbapenem-resistant Enterobacterales (CRE). However, the CZA-resistant CRE strains have been detected worldwide. Therefore, it is critical to screen CZA-resistant CRE strains in colonized patients or a specific population so as to rapidly implement ...
Weiliang Zeng, Wenli Liao, Wenli Liao, Yajie Zhao, Lingbo Wang, Hongyun Shu, Huaiyu Jia, Tao Chen, Ying Zhang, Tieli Zhou, Qing Wu   +10 more
europepmc   +13 more sources

KPC-33 and ompK37 mutations: Unraveling the mechanism of ceftazidime/avibactam resistance in ST11 carbapenem-resistant Klebsiella pneumoniae. [PDF]

PLoS ONE
BackgroundGlobal surveillance indicates rising ceftazidime-avibactam resistance among carbapenem-resistant Klebsiella pneumoniae (CRKP), with sequence type 11 predominating in China. The contribution of blaKPC variants and porin alterations to high-level
Shulong Zhao, Lin Ye, Shuang Song, Jingfang Sun, Jinfeng Xu, Fei Jiang, Haiquan Kang   +6 more
doaj   +2 more sources

KPC-50 Confers Resistance to Ceftazidime-Avibactam Associated with Reduced Carbapenemase Activity [PDF]

Antimicrobial Agents and Chemotherapy, 2020
KPC-50 is a KPC-3 variant identified from a Klebsiella pneumoniae clinical isolate recovered in Switzerland in 2019. Compared to KPC-3, KPC-50 shows (i) a three-amino-acid insertion (Glu-Ala-Val) between amino acids 276 and 277, (ii) an increased affinity to ceftazidime, (iii) a decreased sensitivity to avibactam ...
Poirel, Laurent, Vuillemin, Xavier, Juhas, Mario, Masseron, Amandine, Bechtel-Grosch, Ursina, Tiziani, Simon, Mancini, Stefano, Nordmann, Patrice   +7 more
openaire   +6 more sources

In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales

Antibiotics, 2023
Background: Avibactam, relebactam and vaborbactam are β-lactamase inhibitors that proved their efficiency against KPC-producing Enterobacterales. Regarding their inhibitor activity towards Ambler’s class A extended spectrum β-lactamases (ESBL) and Ambler’
Rémy A. Bonnin, Sandrine Bernabeu, Cécile Emeraud, Thierry Naas, Delphine Girlich, Agnès B. Jousset, Laurent Dortet   +6 more
doaj   +2 more sources

In Vitro Selection of Ceftazidime-Avibactam Resistance in Enterobacteriaceae with KPC-3 Carbapenemase [PDF]

Antimicrobial Agents and Chemotherapy, 2015
ABSTRACT Ceftazidime-avibactam is active against most Enterobacteriaceae isolates with KPC carbapenemases. We investigated whether this activity could be compromised by mutation. Single-step and multistep selections were attempted using ceftazidime-avibactam (avibactam fixed at 1 or 4 μg/ml ...
Livermore, David, Warner, Marina, Jamrozy, Dorota, Mushtaq, Shazad, Nichols, Wright W., Mustafa, Nazim, Woodford, Neil   +6 more
openaire   +5 more sources

Identification of a Novel KPC Variant, KPC-204, Conferring Resistance to Both Carbapenems and Ceftazidime–Avibactam in an ST11 Klebsiella pneumoniae Strain

Microorganisms
This study describes KPC-204, a novel variant of Klebsiella pneumoniae carbapenemase, characterized by a Lys-Asp-Asp (KDD) amino acid insertion at Ambler position 269 deviates from KPC-2.
Yanqiao Gong, Yu Feng, Xiaoju Lv
doaj   +2 more sources

Fitness cost of ceftazidime–avibactam resistance acquisition in carbapenem-resistant hypervirulent Klebsiella pneumoniae [PDF]

BMC Microbiology
Antibiotic-resistant Klebsiella pneumoniae (KP) poses a serious global public health threat. However, research on the resistance mechanisms and accompanying phenotypic changes in carbapenem-resistant hypervirulent KP (CR-hvKP) under antibiotic treatment remains limited.
Huang, Min, Xiao, Sheng-Ping, Zeng, Qing-Hua, Guo, Hua-Ming, Liu, Ya-Ting, Wei, Dan-Dan, Kang, Xiu-Hua   +6 more
openaire   +3 more sources